98 results about "Diabetic complication" patented technology

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention belongs to the technical field of artificial intelligence, and discloses a diabetic complication risk deduction system based on a graph neural network and a knowledge graph, and the system comprises a physiological feature sensing module which collects physiological sensing data of a diabetic patient, carries out the time synchronization and normalization processing of the physiological sensing data, and carries out the prediction of the diabetic complication risk. Separating a stability characteristic component and a disturbance characteristic component; the pathological potential mapping module is used for mapping the stable characteristic component into a basic physiological node and mapping the disturbance characteristic component into a potential pathological activation node on the basis of a semantic structure of a knowledge graph, introducing a pathological potential function and establishing a pathological potential mapping network; the pathology activation recognition module calculates potential pathology energy of each potential pathology activation node in the pathology potential mapping network through a graph neural network, and when the potential pathology energy is greater than a preset potential pathology energy threshold, the potential pathology activation node is marked as a pathology activation source node; and early warning of diabetic complications is realized.

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention relates to the technical field of physiological measurement, in particular to a diabetes symptom automatic detection system which comprises a blood glucose fluctuation analysis module, a polydipsia and polyuria symptom detection module, a decline level evaluation module and a progress stage recognition module. According to the invention, through the correlation analysis of real-time blood glucose monitoring and the diet state of the patient, the change of the blood glucose level is accurately captured, the development trend of the illness state is predicted, the real-time performance of illness state monitoring is enhanced, the medical intervention is more timely and effective, and through the continuous monitoring of the water intake and the urine volume of the patient, the polydipsia and diuresis symptoms of the diabetic patient are timely found, and the patient experience is improved. The correlation between a target symptom and the development of diabetes is determined through data analysis, the recognition capability of early-stage diabetic complications is enhanced, the organ function level is evaluated, the signs of organ damage are recognized, the treatment strategy is helped to be adjusted, the development of complications is prevented, the real-time performance and accuracy of disease monitoring are improved, and the disease diagnosis and treatment efficiency is improved. And the complexity and the cost of long-term treatment are reduced.

The invention discloses nutrition-balanced, sugar-controllable, fat-reducing and staple food nutrition-improving medicated food and a preparation method thereof. The medicated food is prepared from the following raw material components: 5-10% of high-quality protein, 1-10% of high-quality fat-containing food raw materials, 0.8-15% of medicinal and edible traditional Chinese medicines, 5-15% of high-quality carbohydrates, 5-60% of dietary fibers, 2-10% of functional sugar and 1-2% of minerals. The formula food is directly cooked with rice to form rice and porridge or is directly mixed with flour to form cooked wheaten food, so that the contact degree of starch and digestive enzyme and the activity of glycosidase can be reduced, the starch hydrolysis rate can be reduced, and the generation of postprandial blood sugar can be delayed. The formula food is prepared from various functional food raw materials and medicinal and edible food materials, is safe and free of side effects, and can be taken for a long time. All the components supplement each other to achieve a synergistic effect, the glycemic index of a patient can be adjusted, diabetic complications of the patient are improved, and therefore disease rehabilitation of the diabetic patient is promoted.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention discloses a diabetic complication risk assessment method based on unequal-length CGM data, belongs to the field of assessment methods, and aims to solve the problem of how to extract complication related features from unequal-length CGM sequences of diabetic patients and realize efficient risk assessment on the premise of not losing dynamic information as far as possible. The method comprises the following steps: step 1, acquiring a multi-day CGM data sequence of a diabetic patient; 2, performing feature extraction based on the multi-day CGM data sequence to obtain a multi-day CGM sequence feature C; and step 3, inputting the multi-day CGM sequence feature C into the FCNN to obtain the probability that the diabetic suffers from complications.

The invention discloses a traditional Chinese medicine composition for treating type 2 diabetes and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 11-15 parts of radix acanthopanacis semticosi, 5-15 parts of male silkworm moth, 7-17 parts of white ginseng, 5-11 parts of rhizoma polygoni cuspidati, 15-25 parts of rhizoma coptidis, 1-5 parts of cortex cinnamomi, 11-15 parts of fructus ligustri lucidi, 11-15 parts of common fenugreek seed, 7-17 parts of lithocarpus litseifolius, 3-7 parts of raw radix astragali and 1-3 parts of wild lucid ganoderma. , 3-9 parts of tribulus terrestris and 11-17 parts of nigella nigra seeds. The traditional Chinese medicine composition has the effect of balancing and stabilizing blood sugar, is short in treatment course, quick in effect and free of toxic and side effects, and has an excellent curative effect on treating diabetic complications.

The invention relates to a 2-substituted aminobenzothiazole compound and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition containing the compound and application thereof. The 2-substituted aminobenzothiazole compound is a compound as shown in a general formula I and pharmaceutically acceptable salts thereof, wherein substituent groups R1, R2, R3, R4, m, n, X and Y have meanings given in the specification. The invention also relates to application of the compound shown in the general formula I in preparation of drugs for treating and / or preventing sEH-mediated diseases, in particular to application of the compound shown in the general formula I in preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, pain, xerophthalmia, diabetes, diabetic complications, diabetes-related diseases, fibrosis diseases, neurological and mental diseases, ulcerative diseases and the like. # imgabs0 #

The invention relates to the technical field of diabetes prediction, in particular to a risk assessment method and system for diabetic complications, and the method comprises the following steps: obtaining CGM data, and carrying out the preprocessing of the CGM data; dividing the preprocessed CGM data into the CGM data in different time periods; performing feature extraction on the CGM data of each time period; taking the extracted features as input of a machine learning algorithm, and adopting the machine learning algorithm for training; analyzing the influence of the extracted features on diabetic complications to obtain important features; a logistic regression model is adopted, and the corresponding relation between changes of the important features in different time periods and changes of the diabetic complication risk is calculated; according to the corresponding relation, the blood glucose value in the time period corresponding to the features is precisely regulated and controlled. According to the method, the CGM data in one day are divided into different time periods, the influence of the change of the CGM data in each time period on the diabetic complications is analyzed, and support is provided for precise management of the diabetic complications.

The invention discloses a feature selection method for multi-label prediction of diabetic complications, and relates to the technical field of machine learning and medical data processing. The method comprises the following steps: carrying out label layered independent weight calculation on original characteristics of diabetic complications and complication label data to obtain a label weight matrix of a plurality of complications; performing graph regularization optimization based on layered independent weights on the label weight matrix of the multiple complications, training a multi-label classification model, reducing irrelevant and redundant features in the multi-label classification model, and obtaining feature subsets with importance perception, high discrimination and robustness; and screening the original data of the diabetic complications by using the optimized multi-label classification model, calculating a feature contribution matrix, and for positive prediction labels, outputting the first three features of contribution values for constructing the features of diabetic complication prediction. According to the method, key features can be screened out, and the accuracy of model prediction is improved.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

The present invention belongs to the field of preparation of diabetes complication remission agents, and particularly relates to a combined preparation for improving microcirculation of diabetic foot and a preparation method thereof. Starting from platelet-rich plasma, the present invention obtains exosomes containing rich active substances such as growth factors through stimulation with calcium gluconate and the like, and loads protamine nanoparticles to obtain bioactive substances with strong antibacterial ability, which can resist the development process of diabetic foot ulcers. The present invention uses bioactive glass, hydroxyethyl cellulose and the like to stabilize the bioactive substances, prolong the in vitro lifespan of the bioactive substances, and modified carboxymethyl cellulose provides better biodegradation effect. The combined preparation prepared by the present invention has less cytotoxicity, better antibacterial effect, can promote wound healing quickly, and the microcirculation index shows that it can stimulate the change of foot blood flow and improve the condition of foot artery blockage, etc.

The device is used for preventing diabetic feet caused by diabetic complications and comprises a humidifier body and an atomizer body arranged in the humidifier body, a control panel is arranged on the upper surface of the atomizer body, and a foot containing cavity is formed in the portion, located on one side of the atomizer body, of the humidifier body; wherein a water tank, an atomizer head and a control module are arranged in the atomizer body, the water tank is used for storing water, the atomizer head is used for atomizing the water into tiny water drops, and the control module is used for controlling the working state of the atomizer. According to the foot atomizer, the feet can be continuously kept wet, the problems of foot dryness, chap and the like are effectively prevented, the temperature and humidity in the foot containing cavity are monitored in real time through the temperature sensor and the humidity sensor, the working state of the atomizer body is automatically adjusted, and it is ensured that the feet are always in the appropriate temperature and humidity environment.

The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I).Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and / or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

The application discloses a diabetes complication risk assessment method based on unequal length CGM data and belongs to the field of assessment methods. The application aims to solve the problem of how to extract the complication-related features from the unequal length CGM sequence of a diabetes patient and realize efficient risk assessment without losing dynamic information as much as possible. The application comprises the following steps: step 1, acquiring a multi-day CGM data sequence of a diabetes patient; step 2, performing feature extraction based on the multi-day CGM data sequence to obtain multi-day CGM sequence features; and step 3, inputting the multi-day CGM sequence features into an FCNN to obtain the probability of the diabetes patient suffering from complications. C ; step 3, inputting the multi-day CGM sequence features C into an FCNN to obtain the probability of the diabetes patient suffering from complications.

The invention discloses thiazolidinedione or a derivative thereof as well as a preparation method and application thereof, the structural formula of the thiazolidinedione or the derivative thereof is non-substituted or randomly substituted by at least one R, and R is halogen or hydroxyl. An activity detection experiment and a compound dissociation constant test experiment on the inhibition activity of aldose reductase and alpha-glucosidase on the compound prove that the compound disclosed by the invention is an efficient AKR1B1 / alpha-GC double-target inhibitor with excellent membrane permeability, and is capable of relieving hyperglycemia while preventing abnormal metabolism of polyhydric alcohols; by utilizing a double-target collaborative intervention strategy, the application prospect in preparation of related medicines for preventing and / or treating diabetic complications is good.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The invention belongs to the technical field of hippophae rhamnoides fruit residue utilization, and particularly relates to application of hippophae rhamnoides fruit residue extract in preparation of a medicine for treating diabetic complications. Experiments find that the sea buckthorn pomace extract has a high inhibition rate on cholesterol esterase and alpha-amylase, and the sea buckthorn pomace extract mainly contains malvacic acid, aspartic acid, luteolin and vernonic acid, and key targets mainly include IL6, AKT1, TNF and PPARG, and the sea buckthorn pomace extract has a high inhibition rate on cholesterol esterase and alpha-amylase. The fructus hippophae pomace extract plays a role in regulating blood fat regulation, atherosclerosis, HIF-1 signal transduction, AGE-RAGE signal transduction and other pathways in diabetic complications.

The present invention provides the use of pyruvate in the treatment of lipodystrophy syndrome, belonging to the technical field of endocrine and metabolic disease treatment. This invention proposes for the first time the use of pyruvate, such as sodium pyruvate and potassium pyruvate, in the treatment of lipodystrophy syndrome. It has been found that pyruvate can restore atrophic adipose tissue and improve the progression of diabetic complications and acute pancreatitis associated with hypertriglyceridemia, thereby increasing patient survival and improving overall prognosis.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD317 + MSC cells and application of the CD317 + MSC cells to treatment of type 2 diabetes mellitus. The invention researches the characteristics of CD317 + cells in a heterogeneous UC-MSC population, and finds that the FACS is more beneficial to screening of CD317 + MSCs, and the number of the CD317 + MSCs is gradually increased in in-vitro culture. The expression quantity of stem cell characteristic-related genes in the CD317 + MSC subgroup is obviously increased, which indicates that the stem cell is possibly in an undifferentiated state or affects the differentiation potential, but the effect is transiently and gradually weakened along with culture, which explains that the pluripotent differentiation potential and the like are not obviously changed and are not associated with other potential stem cell surface antigens. The research also finds that the cell is a more favorable subgroup, has unique pluripotency and repair / substitution characteristics, can realize stem cell rejuvenation phenotype, can improve pancreas beta cell functions, reduces diabetic complications, enables partial patients to be independent of insulin, and improves the treatment effect on type 2 diabetes mellitus.

This invention belongs to the field of artificial intelligence technology. It discloses a risk prediction system for diabetic complications based on graph neural networks and knowledge graphs. The system includes a physiological feature perception module, which collects physiological perception data from diabetic patients, performs time synchronization and normalization on the data, and separates stable and perturbation feature components; a pathological potential mapping module, which, based on the semantic structure of the knowledge graph, maps stable feature components to basic physiological nodes and perturbation feature components to potential pathological activation nodes, introduces a pathological potential function, and establishes a pathological potential mapping network; and a pathological activation identification module, which calculates the potential pathological energy of each potential pathological activation node in the pathological potential mapping network using a graph neural network. When the potential pathological energy exceeds a preset potential pathological energy threshold, it is marked as a pathological activation source node; thus achieving early warning of diabetic complications.

The invention relates to the technical field of diabetic complication prediction, and discloses a modeling method of a diabetic complication prediction model. The method comprises the following steps: collecting clinical index data of a patient, including blood glucose level, blood pressure value, blood fat content and renal function parameters, and performing standardization processing to generate a standard data set; time sequence features in the data set are extracted, the short-term fluctuation trend and the long-term change rule of each index are calculated through a sliding window algorithm, and a time sequence feature vector is generated; and inputting the vector into a deep feature extraction network formed by multilayer convolution and long and short term memory units, and extracting high-dimensional time sequence feature representation. Based on the representation, a hierarchical clustering algorithm is used for grouping patient groups, and personalized complication risk prediction sub-models are constructed for different groups. And integrating the outputs of all the personalized sub-models, and generating a final diabetic complication prediction result through a weighted voting mechanism.

Disclosed are quinoline compounds having a structural formula represented by the following formula: and wherein Cy, R1, R4a, R4b and n are as described herein. These compounds may be prepared as compositions, e.g., pharmaceutical compositions, or prepared as dosage forms, e.g., pharmaceutical dosage forms, and may be used in the prevention and treatment of various conditions in mammals, including humans, such as, for example, mammals. Including non-limiting examples of diabetic complications, inflammation, neurodegeneration, obesity, cancer, ischemia / reperfusion injury, cardiovascular disease, COVID-19 complications, and other diseases associated with RAGE activity.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

The invention provides a diabetic complication prediction method based on a neural network, and relates to the technical field of artificial intelligence. According to the method, firstly, through a semantic mining unit included in a target complication prediction network, a target complication interference vector is determined; secondly, through a semantic mining unit, according to the obtained target diabetic user data, performing interference removal operation on the target complication interference vector, and outputting a diabetic complication vector; and then, through a semantic analysis unit included in the target complication prediction network, performing semantic analysis operation on the diabetic complication vector, and outputting a target diabetic complication prediction result corresponding to the target diabetic user data. Based on the method, the problem that in the prior art, the reliability of diabetic complication prediction is relatively low can be solved.

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

The invention provides a pharmaceutical active ingredient composition and application thereof in treating diabetes or preventing and treating diabetic complications. The pharmaceutical active ingredient composition provided by the invention comprises a first active ingredient and a second active ingredient, the first active component is at least one of the following components: a DPP-4 inhibitor, pharmaceutically acceptable salts, esters, prodrugs and metabolites thereof, and an SGLT-2 inhibitor, pharmaceutically acceptable salts, esters, prodrugs and metabolites thereof; the second active ingredient is at least one of the following components: coenzyme Q10, pharmaceutically acceptable ester of the coenzyme Q10, R-alpha-lipoic acid, pharmaceutically acceptable salt and ester of the R-alpha-lipoic acid, glutathione, pharmaceutically acceptable salt of the glutathione, resveratrol and pharmaceutically acceptable ester of the resveratrol. The pharmaceutical active ingredient composition provided by the invention has a good hypoglycemic effect, and has remarkable advantages in the aspects of relieving oxidative stress and preventing and treating diabetic complications.